Amgen Inc. again set analysts and investors abuzz with phase II/III data on its protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab, now dubbed Repatha, presented at the American College of Cardiology's (ACC) annual scientific session in San Diego.